Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I

Biochemical and Molecular Medicine

Volumn 58, Issue 2, 1996, Pages 156-167

  Kakkis, Emil D ^a   McEntee, Michael F ^b   Schmidtchen, Artur ^c   Neufeld, Elizabeth F ^c   Ward, Daniel A ^b   Gompf, Rebecca E ^b   Kania, Stephen ^b   Bedolla, Cathy ^a   Chien, Shu Lin ^a   Shull, Robert M ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; LEVO IDURONIDASE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; HISTOPATHOLOGY; HURLER SYNDROME; IMMUNE COMPLEX DISEASE; INTRAVENOUS DRUG ADMINISTRATION; LYSOSOME STORAGE DISEASE; NONHUMAN; PROTEINURIA; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 0030221033     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1996.0044     Document Type: Article

References (32)

1. 1. Kakkis ED, Shull RM, McEntee MF, Schmidtchen A, Neufeld EF. Long-term and high dose enzyme replacement therapy in the canine mucopolysaccharidosis I model. Am J Hum Genet 57:A39(193), 1995. [Abstract]
2. 2. De Duve C. From cytases to lysosomes. Fed Proc 23:1045-1049, 1964.
3. 3. Hers HG. Inborn lysosomal diseases. Prog Gastroent 48:625-633, 1965.
4. 4. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In The Metabolic and Molecular Bases of Inherited Disease (Scriver CR, Beaudet AL, Sly WS, Valle D, Eds.) editors). New York: McGraw-Hill, 1995, pp 2465-2494.
5. 5. Barton NW, Brady RO, Dambrosia JM, Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, Grewal RP, Yu KT, and collaborators. Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464-1470, 1991.
6. 6. Sato Y, Beutler E. Binding, internalization and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Invest 91:1909-1917, 1993.
7. 7. Frantantoni JC, Hall CW, Neufeld EF. The defect in Hurler and Hunter syndromes, II. Deficiency of specific factors involved in mucopolysaccharide degradation. Proc Natl Acad Sci USA 64:360-366, 1969.
8. 8. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: Diagnostic, clinical and biological implications. Hum Mutat 6:288-302, 1995.
9. 9. Scott HS, Anson DS, Orsborn AM, Nelson PV, Clements PR, Morris CP, Hopwood JJ. Human α-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci USA 88:9695-9699, 1991.
10. 10. Stoltzfus LJ, Sosa-Pineda B, Moskowitz SM, Menon KP, Dlott B, Hooper L, Teplow D, Shull RM, Neufeld EF. Cloning and characterization of cDNA encoding canine α-L-iduronidase. J Biol Chem 267:6570-6575, 1992.
11. 11. Moskowitz SM, Dlott B, Chuang PD, Neufeld EF. Cloning and expression of cDNA encoding the human lysosomal enzyme, α-L-iduronidase. FASEB J 6:A77, 1992. [Abstract]
12. 12. Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme α-L-iduronidase in Chinese hamster ovary cells. Protein Expression Purif 5:225-232, 1992.
13. 13. Spellacy E, Shull RM, Constantopoulos G, Neufeld EF. A canine model of human α-L-iduronidase deficiency. Proc Natl Acad Sci USA 80:6091-6095, 1983.
14. 14. Menon KP, Tieu PT, Neufeld EF. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis type I. Genomics 14:763-768, 1992.
15. 15. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in canine model of Hurler syndrome. Proc Natl Acad Sci USA 91:12937-12941, 1994.
16. 16. Bjornsson S. Simultaneous preparation and quantification of proteoglycans by precipitation with Alcian blue. Anal Biochem 210:282-291, 1993.
17. 17. Laboratory Methods in Histotechnology. Washington, DC.: Am. Registry of Pathol. 1992, pp. 162-163.
18. 18. Rome LH, Garvin AJ, Neufeld EF. Human kidney α-L-iduronidase: purification and characterization. Arch Biochem Biophys 189:344-353, 1978.
19. 19. Shull RM, Hastings NE, Selcer RR, Jones JB, Smith JR, Cullen WC, Constantopoulos G. Bone marrow transplantation in canine mucopolysaccharidosis I: Effects within the central nervous system. J Clin Invest 79:435-443, 1987.
20. 20. Sands M, Vogler C, Kyle J, Grubb J, Levy B, Galvin N, Sly W, Birkenmeier E. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 93:2324-2331, 1994.
21. 21. Pardridge WM. Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann NY Acad Sci 692:126-137, 1993.
22. 22. Stahl PD, Wileman TE, Diment S, Shepherd VL. Mannose-specific oligosaccharide recognition by mononuclear phagocytes. Biol Cell 51:215-218, 1984.
23. 23. Prieels JP, Pizzo SV, Glasgow LR, Paulson JC, Hill RL. Hepatic receptor that specifically binds oligosaccharides containing fucosyl α1-3 N-acetylglucosamine linkages. Proc Natl Acad Sci USA 75:2215-2219, 1978.
24. 24. Hajjar KA, Reynolds CM. Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J Clin Invest 93:703-710, 1994.
25. 25. Furbish FS, Krett NL, Barranger JA, Brady RO. Fucose plays a role in the clearance and uptake of glucocerebrosidase by rat liver cells. Biochem Biophys Res Commun 95:1768-1774, 1980.
26. 26. Whitley CB, Ramsay NKC, Kersey JH, Krivit W. Bone marrow transplantation for Hurler syndrome: Assessment of metabolic correction. Birth Defects Orig Artic Ser 22:7-24, 1986.
27. 27. Hobbs JR, Barrett AJ, Chambers D, James DCO, Hugh-Jones K, Byrom N, Henry K, Lucas CF, Rogers TR, Benson PF, Tansley LR, Patrick AD, Mossman J, Young EP. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone marrow transplantation. Lancet 2:709-712, 1981.
28. 28. Hoogebrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, Blanche S, Fischer A. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 345:1398-1402, 1995.
29. 29. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82:1402-1409, 1993.
30. 30. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89:1643-1651, 1993.
31. 31. Roberts HR, Cromartie R. Overview of inhibitors to factor VIII and IX. Prog Clin Biol Res 150:1-18, 1984.
32. 32. Gossain VV, Rovner RR, Mohan K. Systemic allergy to human (recombinant DNA) insulin. Ann Allergy 55:116-118, 1985.